Interferons Command Trim22 to Fight Against Viruses

Total Page:16

File Type:pdf, Size:1020Kb

Interferons Command Trim22 to Fight Against Viruses Cellular & Molecular Immunology (2017) 14, 794–796 & 2017 CSI and USTC All rights reserved 2042-0226/17 $32.00 www.nature.com/cmi LETTER TO THE EDITOR Interferons command Trim22 to fight against viruses Qiaoshi Lian1,2 and Bing Sun1 Cellular & Molecular Immunology (2017) 14, 794–796; doi:10.1038/cmi.2017.76; published online 7 August 2017 he mammalian innate immune sys- infection, leading to liver cirrhosis or Trim22 is an IFN-inducible protein Ttem provides the first line of defen- even hepatocellular carcinoma.3 HCV is that is induced by IFN-α and IFN-γ in sive mechanisms to protect the host an enveloped, positive-sense single- HepG2 cells, an epithelial-like human against invading pathogens. These defen- stranded RNA virus. The genome of liver carcinoma cell line.10 Yang et al. sive responses are initiated by recogni- HCV encodes structural proteins (core, validated the inducible expression of tion of microbial pathogen-associated E1 and E2) and nonstructural proteins trim22 by IFN-α in Huh-7 cells. The molecular patterns (PAMPs), which are (p7, nonstructural (NS) 2, NS3, NS4A, authors presented a direct induction of engaged by conserved germline-encoded NS4B, NS5A and NS5B). During HCV trim22 by HCV infection after 24 h in pattern recognition receptors (PRRs).1 infection, viral dsRNA replicative inter- Huh-7 cells; however, the upregulation Viral infection is always a considerable mediates can be recognized by RIG-I and of trim22 was lower than that noted with threat for public health. During viral MDA5 to induce a type I IFN response, IFN treatment. In addition, the study infection, viral nucleic acids serve as the which is crucial for the host to counter- demonstrated that trim22 was signifi- dominant PAMPs for the host innate act HCV infection.4,5 cantly induced in PBMCs of HCV- immune system, which can be recog- The tripartite motif (TRIM) family is a infected patients following IFN-α treat- nized by diverse PRR families, including well-known superfamily with Ring-finger ment. In addition, trim22 expression Toll-like receptors (TLRs), RIG-I-like E3 ubiquitin ligase activity. The TRIM peaked at 12 h post IFN-α treatment, receptors and cytosolic DNA receptors. family includes greater than 70 members suggesting a potential role of trim22 in α Viral nucleic acid sensing markedly trig- in humans. TRIM family members have IFN- -mediated anti-HCV therapy. gers downstream type I interferon secre- been implicated as critical regulators of Using a reconstructed Huh-7 cell line tion, which thereby activates interferon- innate immune responses against micro- stably expressing the HCV Con1 replicon stimulated genes to exert anti-viral bial pathogens, including anti-viral genome, the authors assessed the anti- 6,7 effects.2 responses. Virus recognition-triggered HCV activity of trim22. Overexpression Hepatitis C virus (HCV) is a danger- type I interferon could subsequently of trim22 markedly inhibited HCV ous human pathogen that infects over induce numerous TRIM proteins expres- NS5A protein levels and HCV replicon 170 million individuals worldwide. HCV sion, which are crucial for restricting levels, and trim22 knockdown greatly infection easily develops into a persistent viral infection via either regulating innate enhanced HCV replication activity that signaling pathways or serving as viral occurred upon IFN treatment but not at 8 1State Key Laboratory of Cell Biology, CAS Center restriction factors. Trim22 is a typical steady state. for Excellence in Molecular Cell Science, Shang- TRIM family protein that restricts the Assessment of the mechanism indi- hai Institute of Biochemistry and Cell Biology, replication of various viruses via distinct cated that trim22 directly interacted with Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai manners, for example, inhibiting HIV NS5A. NS5A is an HCV nonstructural 200031, China and 2University of Chinese Acad- particle production,9 suppressing the protein that is critical for both HCV emy of Sciences, Beijing 100049, China activity of hepatitis B virus core replication and assembly.13 The crosstalk Correspondence: Professor B Sun, PhD, State 10 fl Key Laboratory of Cell Biology, CAS Center for promoter and targeting in uenza A of host factors and viral factors is a Excellence in Molecular Cell Science, Shanghai virus nucleoprotein for degradation.11 consequence of co-evolution. Viral fac- Institute of Biochemistry and Cell Biology, In our previous work, Yang et al.12 tors typically target host factors to avoid Chinese Academy of Sciences, 320 Yueyang identified the anti-viral role of trim22 immune sensing or immune clearance. Road, Shanghai 200031, China. E-mail: [email protected] on the inhibition of HCV replication Conversely, many host factors can also Received: 30 June 2017; Accepted: 1 July 2017 (Figure 1). bind to viral factors to restrict viral Interferons command Trim22 to fight against viruses QLianandBSun 795 Figure 1 Trim22 is a broad anti-viral host factor. During virus infection, including HIV, HBV, influenza A virus and HCV, viral nucleic acids are detected by host PRRs (such as TLR3/7/8/9, RIG-I/MDA5, cGAS/DDX41/IFI16). Recognition of viral DNA/RNA triggers type I interferon production dependent on IRF3 activation. Secreted IFN-α/β bind to IFNAR to activate the Stat1-Stat2 heterodimer to induce the expression of trim22, a critical viral restriction factor, protecting the host against diverse viral infections. replication. NS5A targets Myd88 to activity of HCV replication was deter- HCV infections are associated with spe- attenuate TLR signaling and interacts mined by a Huh-7-Con1-rep cell system cial TRIM22 SNPs in the clinic.14 The with PKR to interfere with HCV RNA rather than direct HCV infection. Thus, reported viruses targeted by trim22 vary replication.13 However, few host factors whether trim22 indeed restricts HCV from RNA viruses to DNA viruses and have been identified as targeting NS5A. virus infection in vivo remains to be single-strand viruses to double-strand et al. fi Here Yang identi ed interactions further validated. Another important viruses, displaying little specificity. More with trim22 and NS5A via SPRY domain question involves evaluating trim22 interestingly, trim22 restricts the infec- and domain 1, respectively. The interac- expression levels in healthy donors and tion of these viruses through largely tion rendered trim22 as an ubiquitin HCV-infected patients to determine distinct mechanisms. Hence, trim22 is a ligase of NS5A. Overexpression of trim22 whether HCV infection induces trim22 broad and multifunctional host anti-viral specifically decreased NS5A protein levels upregulation in vivo. Following this factor induced by interferons. rather than other HCV structural or study, another group confirmed the nonstructural proteins. Moreover, endo- protective role of trim22 against HCV CONFLICT OF INTEREST genous NS5A could be ubiquitinated by and uncovered the clinical significance of The authors declare no conflict of interest. trim22. IFN treatment induced ubiquiti- trim22 for IFN-α-mediated HCV ther- nation of endogenous NS5A. However, apy. Medrano et al. analyzed whether the authors did not map the ubiquitina- single nucleotide polymorphisms (SNPs) TRIM22 TRIM5 tion type and ubiquitination site of NS5A at and genes were 1 Broz P, Monack DM. Newly described pat- by E3 ligase trim22, which is crucial to associated with liver fibrosis and tern recognition receptors team up against understand the regulatory mechanism of response to IFN-α plus ribavirin therapy intracellular pathogens. Nat Rev Immunol 2013; 13:551–565. trim22 on HCV infection. Overall, the in HIV/HCV co-infected patients. The 2 Yan N, Chen ZJ. Intrinsic antiviral immunity. study provides molecular insights to TRIM22 rs1063303 GG genotype is a Nat Immunol 2012; 13:214–222. better understand IFN-α-mediated sensitive SNP for liver fibrosis in HIV/ 3 Lavanchy D. The global burden of hepatitis – HCV infection therapy. HCV co-infected patients.14 C. Liver Int 2009; 29:74 81. 4 Hei L, Zhong J. Laboratory of genetics and Some important questions that arise Notably, trim22 is crucial for the physiology 2 (LGP2) plays an essential role from this study should be further restriction of infection by diverse viruses, in hepatitis C virus infection-induced inter- fl feron responses. Hepatology 2017; 65: explored. What is the restriction activity including HIV, in uenza A virus, HBV, – 15 1478 1491. of trim22 against HCV infection? The herpesvirus and HCV (Figure 1). 5 Cao X, Ding Q, Lu J, Tao W, Huang B, Zhao Y present trim22-mediated inhibition Among these viruses, HIV, HBV and et al. MDA5 plays a critical role in interferon Cellular & Molecular Immunology Interferons command Trim22 to fight against viruses QLianandBSun 796 response during hepatitis C virus infection. Production by Induction of TRIM22. PLoS 13 Wong M-T, Chen SSL. Emerging roles of J Hepatol 62:771–778. Pathog 2008; 4: e1000007. interferon-stimulated genes in the innate 6 Kawai T, Akira S. Regulation of innate 10 Gao B, Duan Z, Xu W, Xiong S. Tripartite immune response to hepatitis C virus infec- immune signalling pathways by the tripartite motif-containing 22 inhibits the activity of tion. Cell Mol Immunol 2016; 13:11–35. motif (TRIM) family proteins. EMBO Mol hepatitis B virus core promoter, which is 14 Medrano LM, Rallón N, Berenguer J, Jimé- – Med 2011; 3:513 527. dependent on nuclear-located RING domain. nez-Sousa MA, Soriano V, Aldámiz-Echevar- 7 Versteeg Gijs A, Rajsbaum R, Sánchez-Apar- Hepatology 2009; 50:424–433. ria T et al. Relationship of TRIM5 and icio Maria T, Maestre Ana M, Valdiviezo J, 11 Di Pietro A, Kajaste-Rudnitski A, Oteiza A, TRIM22 polymorphisms with liver disease Shi M et al. The E3-ligase TRIM family of Nicora L, Towers GJ, Mechti N et al. and HCV clearance after antiviral therapy in proteins regulates signaling pathways trig- TRIM22 inhibits influenza A virus infection gered by innate immune pattern-recognition HIV/HCV coinfected patients.
Recommended publications
  • Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1
    www.nature.com/scientificreports OPEN Reversible Human Immunodefciency Virus Type-1 Latency in Primary Human Received: 11 January 2018 Accepted: 13 August 2018 Monocyte-Derived Macrophages Published: xx xx xxxx Induced by Sustained M1 Polarization Francesca Graziano1,4, Giulia Aimola1, Greta Forlani 2, Filippo Turrini 1, Roberto S. Accolla2, Elisa Vicenzi1 & Guido Poli1,3 We have reported that short-term stimulation of primary human monocyte-derived macrophages (MDM) with interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), i.e. M1 polarization, leads to a signifcant containment of virus replication. Here we show that M1-MDM restimulation with these cytokines 7 days after infection (M12 MDM) promoted an increased restriction of HIV-1 replication characterized by very low levels of virus production near to undetectable levels. In comparison to control and M1-MDM that were not restimulated, M12 MDM showed a stronger reduction of both total and integrated HIV DNA as well as of viral mRNA expression. M12 MDM were characterized by an upregulated expression of restriction factors acting at the level of reverse transcription (RT), including apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) and APOBEC3G, but not SAM domain and HD domain-containing protein 1 (SAMHD1). M12 MDM also showed an increased expression of Class II Transactivator (CIITA) and Tripartite Motif22 (TRIM22), two negative regulators of proviral transcription, whereas expression and phosphorylation of transcriptional inducers of HIV-1, such as nuclear factor kB (NF-kB) and signal transducer and activator of transcription 1 (STAT1), were not impaired in these cells. The almost quiescent state of the infection in M12 MDM was promptly reversed by coculture with mitogen-stimulated leukocytes or cell incubation with their fltered culture supernatant.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Identification of C3 As a Therapeutic Target for Diabetic Nephropathy By
    www.nature.com/scientificreports OPEN Identifcation of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis ShuMei Tang, XiuFen Wang, TianCi Deng, HuiPeng Ge & XiangCheng Xiao* The pathogenesis of diabetic nephropathy is not completely understood, and the efects of existing treatments are not satisfactory. Various public platforms already contain extensive data for deeper bioinformatics analysis. From the GSE30529 dataset based on diabetic nephropathy tubular samples, we identifed 345 genes through diferential expression analysis and weighted gene coexpression correlation network analysis. GO annotations mainly included neutrophil activation, regulation of immune efector process, positive regulation of cytokine production and neutrophil-mediated immunity. KEGG pathways mostly included phagosome, complement and coagulation cascades, cell adhesion molecules and the AGE-RAGE signalling pathway in diabetic complications. Additional datasets were analysed to understand the mechanisms of diferential gene expression from an epigenetic perspective. Diferentially expressed miRNAs were obtained to construct a miRNA-mRNA network from the miRNA profles in the GSE57674 dataset. The miR-1237-3p/SH2B3, miR-1238-5p/ ZNF652 and miR-766-3p/TGFBI axes may be involved in diabetic nephropathy. The methylation levels of the 345 genes were also tested based on the gene methylation profles of the GSE121820 dataset. The top 20 hub genes in the PPI network were discerned using the CytoHubba tool. Correlation analysis with GFR showed that SYK, CXCL1, LYN, VWF, ANXA1, C3, HLA-E, RHOA, SERPING1, EGF and KNG1 may be involved in diabetic nephropathy. Eight small molecule compounds were identifed as potential therapeutic drugs using Connectivity Map. It is estimated that a total of 451 million people sufered from diabetes by 2017, and the number is speculated to be 693 million by 2045 1.
    [Show full text]
  • Epigenetic Regulation of Intestinal Peptide Transporter PEPT1
    Wang et al. Cell Death and Disease (2021) 12:532 https://doi.org/10.1038/s41419-021-03814-5 Cell Death & Disease ARTICLE Open Access Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization Yanhong Wang1,JiaqiWang1, Lingrong Yang2, Liqing Qiu2,YuhuiHua2,ShixiuWu3,SuZeng1,LushanYu1 and Xiaoli Zheng3 Abstract Human intestinal peptide transporter PEPT1 is commonly repressed in human colorectal cancer (CRC), yet its relationship with sensitivity to the common CRC treatment ubenimex has not previously been elucidated. In this study, we confirmed PEPT1 suppression in CRC using real-time quantitative polymerase chain reaction and western blotting and then investigated the underlying epigenetic pathways involved using bisulfite sequencing, chromatin immunoprecipitation, siRNA knockdown, and reporter gene assays. We found that PEPT1 transcriptional repression was due to both DNMT1-mediated DNA methylation of the proximal promoter region and HDAC1-mediated histone deacetylation, which blocked P300-mediated H3K18/27Ac at the PEPT1 distal promoter. Finally, the effects of the epigenetic activation of PEPT1 on the CRC response to ubenimex were evaluated using sequential combination therapy of decitabine and ubenimex both in vitro and in xenografts. In conclusion, epigenetic silencing of PEPT1 due to increased DNMT1 and HDAC1 expression plays a vital role in the poor response of CRC to ubenimex. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction advanced or metastatic CRC2. The resistance of malignant Colorectal cancer (CRC) is the third most commonly tumor cells to chemotherapy is a crucial reason for poor diagnosed cancer and the second most deadly cancer survival among CRC patients. One explanation for this worldwide, with an estimated over 1.9 million new cases multidrug resistance (MDR) to cancer chemotherapy is and 935,000 deaths recorded in 20201.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • UNIVERSITY of CALIFORNIA RIVERSIDE Investigations Into The
    UNIVERSITY OF CALIFORNIA RIVERSIDE Investigations into the Role of TAF1-mediated Phosphorylation in Gene Regulation A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Cell, Molecular and Developmental Biology by Brian James Gadd December 2012 Dissertation Committee: Dr. Xuan Liu, Chairperson Dr. Frank Sauer Dr. Frances M. Sladek Copyright by Brian James Gadd 2012 The Dissertation of Brian James Gadd is approved Committee Chairperson University of California, Riverside Acknowledgments I am thankful to Dr. Liu for her patience and support over the last eight years. I am deeply indebted to my committee members, Dr. Frank Sauer and Dr. Frances Sladek for the insightful comments on my research and this dissertation. Thanks goes out to CMDB, especially Dr. Bachant, Dr. Springer and Kathy Redd for their support. Thanks to all the members of the Liu lab both past and present. A very special thanks to the members of the Sauer lab, including Silvia, Stephane, David, Matt, Stephen, Ninuo, Toby, Josh, Alice, Alex and Flora. You have made all the years here fly by and made them so enjoyable. From the Sladek lab I want to thank Eugene, John, Linh and Karthi. Special thanks go out to all the friends I’ve made over the years here. Chris, Amber, Stephane and David, thank you so much for feeding me, encouraging me and keeping me sane. Thanks to the brothers for all your encouragement and prayers. To any I haven’t mentioned by name, I promise I haven’t forgotten all you’ve done for me during my graduate years.
    [Show full text]
  • Variants in TRIM22 That Affect NOD2 Signaling Are Associated with Very Early Onset Inflammatory Bowel Disease
    Accepted Manuscript Variants in TRIM22 that Affect NOD2 Signaling Are Associated With Very Early Onset Inflammatory Bowel Disease Qi Li, Cheng Hiang Lee, Lauren A. Peters, Lucas A. Mastropaolo, Cornelia Thoeni, Abdul Elkadri, Tobias Schwerd, Jun Zhu, Bin Zhang, Yongzhong Zhao, Ke Hao, Antonio Dinarzo, Gabriel Hoffman, Brian A. Kidd, Ryan Murchie, Ziad Al Adham, Conghui Guo, Daniel Kotlarz, Ernest Cutz, Thomas D. Walters, Dror S. Shouval, Mark Curran, Radu Dobrin, Carrie Brodmerkel, Scott B. Snapper, Christoph Klein, John H. Brumell, Mingjing Hu, Ralph Nanan, Brigitte Snanter-Nanan, Melanie Wong, Francoise Le Deist, Elie Haddad, Chaim M. Roifman, Colette Deslandres, Anne M. Griffiths, Kevin J. Gaskin, Holm H. Uhlig, Eric E. Schadt, Aleixo M. Muise PII: S0016-5085(16)00123-2 DOI: 10.1053/j.gastro.2016.01.031 Reference: YGAST 60258 To appear in: Gastroenterology Accepted Date: 22 January 2016 Please cite this article as: Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, Hao K, Dinarzo A, Hoffman G, Kidd BA, Murchie R, Al Adham Z, Guo C, Kotlarz D, Cutz E, Walters TD, Shouval DS, Curran M, Dobrin R, Brodmerkel C, Snapper SB, Klein C, Brumell JH, Hu M, Nanan R, Snanter-Nanan B, Wong M, Le Deist F, Haddad E, Roifman CM, Deslandres C, Griffiths AM, Gaskin KJ, Uhlig HH, Schadt EE, Muise AM, Variants in TRIM22 that Affect NOD2 Signaling Are Associated With Very Early Onset Inflammatory Bowel Disease, Gastroenterology (2016), doi: 10.1053/j.gastro.2016.01.031. This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • The Viral Oncoproteins Tax and HBZ Reprogram the Cellular Mrna Splicing Landscape
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape Charlotte Vandermeulen1,2,3, Tina O’Grady3, Bartimee Galvan3, Majid Cherkaoui1, Alice Desbuleux1,2,4,5, Georges Coppin1,2,4,5, Julien Olivet1,2,4,5, Lamya Ben Ameur6, Keisuke Kataoka7, Seishi Ogawa7, Marc Thiry8, Franck Mortreux6, Michael A. Calderwood2,4,5, David E. Hill2,4,5, Johan Van Weyenbergh9, Benoit Charloteaux2,4,5,10, Marc Vidal2,4*, Franck Dequiedt3*, and Jean-Claude Twizere1,2,11* 1Laboratory of Viral Interactomes, GIGA Institute, University of Liege, Liege, Belgium.2Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.3Laboratory of Gene Expression and Cancer, GIGA Institute, University of Liege, Liege, Belgium.4Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. 5Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.6Laboratory of Biology and Modeling of the Cell, CNRS UMR 5239, INSERM U1210, University of Lyon, Lyon, France.7Department of Pathology and Tumor Biology, Kyoto University, Japan.8Unit of Cell and Tissue Biology, GIGA Institute, University of Liege, Liege, Belgium.9Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven, Leuven, Belgium.10Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.11Lead Contact. *Correspondence: [email protected]; [email protected]; [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021.
    [Show full text]
  • Virtual Chip-Seq: Predicting Transcription Factor Binding
    bioRxiv preprint doi: https://doi.org/10.1101/168419; this version posted March 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Virtual ChIP-seq: predicting transcription factor binding 2 by learning from the transcriptome 1,2,3 1,2,3,4,5 3 Mehran Karimzadeh and Michael M. Hoffman 1 4 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada 2 5 Princess Margaret Cancer Centre, Toronto, ON, Canada 3 6 Vector Institute, Toronto, ON, Canada 4 7 Department of Computer Science, University of Toronto, Toronto, ON, Canada 5 8 Lead contact: michael.hoff[email protected] 9 March 8, 2019 10 Abstract 11 Motivation: 12 Identifying transcription factor binding sites is the first step in pinpointing non-coding mutations 13 that disrupt the regulatory function of transcription factors and promote disease. ChIP-seq is 14 the most common method for identifying binding sites, but performing it on patient samples is 15 hampered by the amount of available biological material and the cost of the experiment. Existing 16 methods for computational prediction of regulatory elements primarily predict binding in genomic 17 regions with sequence similarity to known transcription factor sequence preferences. This has limited 18 efficacy since most binding sites do not resemble known transcription factor sequence motifs, and 19 many transcription factors are not even sequence-specific. 20 Results: 21 We developed Virtual ChIP-seq, which predicts binding of individual transcription factors in new 22 cell types using an artificial neural network that integrates ChIP-seq results from other cell types 23 and chromatin accessibility data in the new cell type.
    [Show full text]
  • Zenglv Fumai Granule Protects Cardiomyocytes Against Hypoxia/Reoxygenation-Induced Apoptosis Via Inhibiting TRIM28 Expression
    MOLECULAR MEDICINE REPORTS 23: 171, 2021 Zenglv Fumai Granule protects cardiomyocytes against hypoxia/reoxygenation-induced apoptosis via inhibiting TRIM28 expression XIAO-HUA ZHANG1, HONG-YU ZHAO2, YU WANG2, LIN DI2, XIN-YU LIU2, FENG QIAN1 and SHU-RONG LIU1 1Department of Cardiovascular Diseases, The First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences; 2Drug Pharmacology and Toxicology Evaluation Center, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130021, P.R. China Received April 14, 2020; Accepted November 23, 2020 DOI: 10.3892/mmr.2020.11810 Abstract. Myocardial ischemia/reperfusion (MIR) injury, limited by the action of ROS inhibitor N-acetyl-L-cysteine. In which occurs following acute myocardial infarction, can addition, the mRNA and protein levels of antioxidant enzyme cause secondary damage to the heart. Tripartite interaction glutathione peroxidase (GPX)1 were significantly downregu- motif (TRIM) proteins, a class of E3 ubiquitin ligases, have lated in H/R-injured cardiomyocytes. TRIM28 knockdown been recognized as critical regulators in MIR injury. Zenglv restored GPX1 protein levels but had no effect on mRNA Fumai Granule (ZFG) is a clinical prescription for the treat- expression levels. Co-immunoprecipitation and ubiquitination ment of sick sinus syndrome, a disease that is associated assays demonstrated that TRIM28 negatively regulated GPX1 with MIR injury. The present study aimed to investigate the via ubiquitination. In sum, the present study revealed that ZFG effect of ZFG on MIR injury and to determine whether ZFG attenuated H/R-induced cardiomyocyte apoptosis by regu- exerts its effects via regulation of TRIM proteins. In order lating the TRIM28/GPX1/ROS pathway.
    [Show full text]
  • An Influenza Virus-Triggered SUMO Switch Orchestrates Co-Opted Endogenous Retroviruses to Stimulate Host Antiviral Immunity
    An influenza virus-triggered SUMO switch orchestrates co-opted endogenous retroviruses to stimulate host antiviral immunity Nora Schmidta, Patricia Dominguesa,1,2, Filip Golebiowskia,1, Corinna Patzinaa,3, Michael H. Tathamb, Ronald T. Hayb, and Benjamin G. Halea,4 aInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland; and bCentre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom Edited by Stephen P. Goff, Columbia University Medical Center, New York, NY, and approved July 15, 2019 (received for review April 24, 2019) Dynamic small ubiquitin-like modifier (SUMO) linkages to diverse hypothesis that stress-induced host-derived self elements may have cellular protein groups are critical to orchestrate resolution of stresses been co-opted to promote antiviral IFN-mediated defenses. such as genome damage, hypoxia, or proteotoxicity. Defense against SUMOylation is a dynamic posttranslational modification of pathogen insult (often reliant upon host recognition of “non-self” protein lysine residues that is crucial for regulating many cellular nucleic acids) is also modulated by SUMO, but the underlying mech- processes, including transcription, mRNA processing, chromatin anisms are incompletely understood. Here, we used quantitative remodeling, DNA replication, and DNA damage responses (14). SILAC-based proteomics to survey pan-viral host SUMOylation re- Importantly, SUMOylation is highly stress-responsive, and is a sponses, creating a resource of almost 600 common and unique critical mediator in the resolution of cellular insults, including SUMO remodeling events that are mounted during influenza A and hypoxia, heat shock, and genotoxic stresses (15). The small B virus infections, as well as during viral innate immune stimulation.
    [Show full text]
  • Identification of a Potential Tumor Suppressor Gene, UBL3, in Non-Small Cell Lung Cancer
    Cancer Biol Med 2020. doi: 10.20892/j.issn.2095-3941.2019.0279 ORIGINAL ARTICLE Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer Xinchun Zhao1,2,3, Yongchun Zhou4, Qian Hu2,5, Sanhui Gao2,3, Jie Liu2,3, Hong Yu2,5, Yanfei Zhang2,3, Guizhen Wang2,3, Yunchao Huang4, Guangbiao Zhou2,3 1School of Life Sciences, University of Science and Technology of China, Hefei 230026, China; 2State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 3State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; 4Department of Thoracic Surgery, the Third Affiliated Hospital of Kunming Medical University, Kunming 650106, China;5 School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China ABSTRACT Objective: Oncogenes have been shown to be drivers of non-small cell lung cancer (NSCLC), yet the tumor suppressing genes involved in lung carcinogenesis remain to be systematically investigated. This study aimed to identify tumor suppressing ubiquitin pathway genes (UPGs) that were critical to lung tumorigenesis. Methods: The 696 UPGs were silenced by an siRNA screening in NSCLC cells; the potential tumor suppressing UPGs were analyzed, and their clinical significance was investigated. Results: We reported that silencing of 11 UPGs resulted in enhanced proliferation of NSCLC cells, and four UPGs (UBL3, TRIM22, UBE2G2, and MARCH1) were significantly downregulated in tumor samples compared to that in normal lung tissues and their expression levels were positively associated with overall survival (OS) of NSCLC patients.
    [Show full text]